Unibail-Rodamco-Westfield (URW): Issuance of CDIs and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
777
Unibail-Rodamco-Westfield (URW): Issuance of CDIs and despatch of holding statements

Paris, Amsterdam, Sydney,  June 8, 2018 Press release

Unibail-Rodamco-Westfield (URW): Issuance of CDIs and despatch of holding statements

 

Unibail-Rodamco SE ("Unibail-Rodamco") and WFD Unibail-Rodamco N.V. ("WFD-UR"), listed under the Australian Securities Exchange ("ASX") trading name of Unibail-Rodamco-Westfield, advise that in connection with the acquisition of Westfield Corporation:

·661,694,860 CHESS Depositary Interests ("CDIs") were issued today; and

·CHESS allotment confirmation notices and issuer-sponsored holding statements in relation to the CDIs will be despatched today.

20 CDIs collectively represent a beneficial ownership interest in one Stapled Share, being one Unibail-Rodamco ordinary share and one WFD-UR class A share stapled together.

CDIs commenced trading on ASX on a deferred settlement basis on May 31, 2018. It is expected that CDIs will commence trading on a normal settlement basis on June 12, 2018.

As at June 7, 2018, immediately following the acquisition of Westfield Corporation, Unibail-Rodamco and WFD-UR had the following securities on issue:

·138,282,967 Stapled Shares quoted on Euronext Paris and Euronext Amsterdam (but which are not quoted on ASX), of which:

·33,084,743 Stapled Shares underlie the 661,694,860 CDIs which have been issued; and

·the balance, being 105,198,224 do not underlie any CDIs;

·93,248,315 unquoted class B shares in WFD-UR;

·2,707,734 unquoted Unibail-Rodamco stock options exercisable at various prices and expiring on various dates (each of which is convertible into Stapled Shares on a 1:1 basis);

· 197,510 unquoted Unibail-Rodamco performance shares exercisable at various prices and expiring on various dates (each of which is convertible into Stapled Shares on a 1:1 basis);

· 5,847 unquoted bonds ('ORAs') redeemable in Stapled Shares exercisable at various prices and expiring on various dates (each of which is convertible into Stapled Shares on a 1:1.25 basis);

·1,735,749 unquoted bonds ('2014 ORNANEs') redeemable in cash and/or in new and/or existing Stapled Shares exercisable at various prices and expiring on various dates (each of which is convertible into Stapled Shares on a 1:1.16 basis);

·1,441,462 unquoted bonds ('2015 ORNANEs') redeemable in cash and/or in new and/or existing Stapled Shares exercisable at various prices and expiring on various dates (each of which is convertible into Stapled Shares on a 1:1.01 basis).

  Timetable

Event Indicative Date
Issue of CDIs to Scheme Participants June 8, 2018*
Last day of deferred settlement trading of CDIs on ASX June 8, 2018*
CDIs expected to commence trading on ASX on a normal settlement basis June 12, 2018*
The dates marked * in the timetable above are references to dates in Sydney (Australia), rather than to dates in Paris (France)

For further information, please contact: Investor Relations  Maarten Otte  +33 1 76 77 58 02  maarten.otte@unibail-rodamco.com

Media Relations  Nathalie Feld  +33 1 76 77 57 94 nathalie.feld.contractor@unibail-rodamco.com

 

About Unibail-Rodamco-Westfield

Unibail-Rodamco-Westfield is the premier global developer and operator of flagship shopping destinations. With a portfolio valued at €62 Bn as at 31 December 2017, of which 88% in retail, 7% in offices and 6% in convention & exhibition venues, the Group owns and operates 102 shopping centres, of which 56 are flagships in the most dynamic cities in Europe and the United States. Its centres welcome 1.2 billion visits per year. Present in 2 continents and in 13 countries, Unibail-Rodamco-Westfield provides a unique platform for retailers and brand events, and offers an exceptional and constantly renewed experience for customers.

With the support of its 3,700 professionals and an unparalleled track-record and know-how, Unibail-Rodamco-Westfield is ideally positioned to generate superior value and develop world-class projects. The Group has the largest development pipeline in the industry, worth €13 Bn.

Unibail-Rodamco-Westfield distinguishes itself by its Better Places 2030 agenda, that sets its ambition to create better places that respect the highest environmental standards and contribute to better cities.

Unibail-Rodamco-Westfield is listed on Euronext Amsterdam and Euronext Paris (Euronext ticker: URW). A secondary listing has been established in Australia through Chess Depositary Interests. The Group benefits from an A rating from both Standard & Poor's and Fitch Ratings, and from an A2 rating from Moody's.

For more information, please visit www.urw.com

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Delhi Pushes Innovation Against Dryland Challenges

Updated Category News Views 5

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 3

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 7

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 5

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
Silk Road Maritime Extends Its Global Reach in 2026

Updated Category News Views 4

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

Continue Reading
Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 3

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 3

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading
PathoSearch: A New Era in Pathology With Visual Search

Updated Category News Views 7

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating the Pioneers: Results of the 2025 Belonging Awards

Updated Category News Views 242

Introduction to the 2025 Belonging Awards The 2025 Belonging Awards stand as a testament to organizations dedicated to fostering an inclusive workplace. This year, the awards, organized by the Employer Branding Institute, saw a remarkable competition among companies globally, showcasing their commitment to Diversity, Equity, and Inclusion (DEI). The extensive evaluation...

Continue Reading
AI Innovations Driving Growth in Hypothyroidism Market

Updated Category News Views 183

The Growing Hypothyroidism Market and Its Innovations The global hypothyroidism market is on the brink of significant expansion, with projections indicating a remarkable growth of USD 789.8 million over the upcoming years. This growth is fueled by innovative advancements and strategic approaches within the healthcare sector. The market is expected to exhibit an impressive...

Continue Reading
Richmond Heights Celebrates 75 Years with Inspiring Stories

Updated Category News Views 273

Celebating 75 Years of Richmond Heights The Richmond Heights community recently came together for a significant milestone, marking 75 years of rich history and cultural diversity. The celebration was not only about the past; it was a heartfelt acknowledgment of the leaders who have molded this extraordinary place over decades. A Tribute to Community Leaders This special...

Continue Reading
Investigation Launched into Dyne Therapeutics Over Stock Drop

Updated Category News Views 82

Investigation Launched into Dyne Therapeutics Following Stock Decline Dyne Therapeutics, Inc. (NASDAQ: DYN), recognized for its groundbreaking approaches to treating muscular dystrophy, is currently facing scrutiny as Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential claims on behalf of investors. This action follows some concerning news...

Continue Reading
Taseko Mines: Highlights from Q1 Earnings Report and Future Plans

Updated Category News Views 211

Insight into Taseko Mines Limited's Q1 2025 Performance Taseko Mines Limited (TSX: TKO; NYSE American: TGB; LSE: TKO), based in Vancouver, British Columbia, is making waves in the mining sector with its compelling first quarter earnings report for 2025. The company disclosed an Adjusted EBITDA of $34 million and earnings from mining operations before depletion and...

Continue Reading